Acadesine for patients with relapsed/refractor... - CLL Support

CLL Support

23,253 members39,949 posts

Acadesine for patients with relapsed/refractory (CLL). Like fludarabine but very different.

Cllcanada profile image
CllcanadaTop Poster CURE Hero
2 Replies

Acadesine, , 5-aminoimidazole-4-carboxamide- 1-D-ribofuranoside or AICA-riboside, is a water soluble nucleoside with a different mechanism of action compared to currently approved nucleoside analogs (e.g., fludarabine).

Of importance...

Acadesine is not reliant on the p53 tumor suppressor or ataxia telangiectasia mutated (ATM) proteins to drive apoptosis, and hence, the absence/loss of function of these proteins in patients with CLL should not affect the activity of acadesine.

This is an important issue because alterations of either p53 or ATM are related to resistance to chemotherapy in CLL

link.springer.com/content/p...

Stay tuned...early days.

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
2 Replies
keepfit123 profile image
keepfit123

Acadesine sounds like another useful drug for CLL . Does the absence /loss of function of P.53 mean you are 17p deleted.

Cllcanada profile image
CllcanadaTop Poster CURE Hero

Yes and no...TP53 is a gene that encodes a tumor supressor protein called p53 and it is often deleted in 17p deletion...but some times it is mutated or disfunctional...it depend on the locus and size of the missing bit of chromosone...

more

asco.org/ASCOv2/Meetings/Ab...

Not what you're looking for?

You may also like...

Has anyone with TP53 changes been diagnosed with Li-Fraumeni Syndrome?

I know TP53 plays a role in diagnosing and treating CLL, but I also found that Li-Fraumeni and TP53...
Wishing1202 profile image

Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL

Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
lankisterguy profile image
Volunteer

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent...
Jm954 profile image
Administrator

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL

This is an abstract from the Lancet article. There's a fair bit of detail missing regarding the...
Jm954 profile image
Administrator

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
AussieNeil profile image
Partner

Moderation team

See all
Newdawn profile image
NewdawnAdministrator
Jm954 profile image
Jm954Administrator
AussieNeil profile image
AussieNeilAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.